Research progress of SPP1 in cancer regulation: Tumorigenesis, metastasis, tumor microenvironment, immunity and therapeutic targets (Review)
International Journal of Oncology · 14.10.2026 · 69 (6) · 1-22
DOI: 10.3892/ijo.2026.5949 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 14.10.2026. Verfasst von Yujun Xia und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, P.R. China. Hauptthemen laut MEDLINE: Osteopontin, Tumor Microenvironment, Neoplasms. Die Arbeit nennt 167 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Secreted phosphoprotein 1 (SPP1, also known as osteopontin, OPN) is a multifunctional matricellular glycoprotein that is aberrantly overexpressed in nearly all major human malignancies. It functions as a central signaling hub that drives tumor initiation, sustains cancer stemness, accelerates invasion and metastasis, remodels the tumor microenvironment (TME), and mediates immune evasion. SPP1 exerts its oncogenic effects by binding to integrin family receptors (αvβ3, αvβ5, α5β1) and CD44 variants, thereby activating canonical oncogenic signaling cascades including PI3K/AKT, NF‑κB, MAPK/ERK and Wnt/β‑catenin. Beyond cancer‑cell‑autonomous functions, SPP1 orchestrates a complex immunosuppressive TME by modulating tumor‑associated macrophages, cancer‑associated fibroblasts, myeloid‑derived suppressor cells, regulatory T cells (Tregs) and cytotoxic T‑cell activity. Preclinical studies have validated SPP1 as a promising therapeutic target, with strategies including neutralizing antibodies, RNA aptamers, small‑molecule inhibitors, RNA interference and combination immunotherapy showing potent antitumor efficacy. The present review systematically summarizes the molecular basis of SPP1, its receptor‑mediated signaling, multifaceted regulatory roles in tumor biology, TME remodeling, immune suppression and advances in SPP1‑targeted therapy. Current challenges, emerging concepts and future directions to translate SPP1‑targeted interventions into clinical practice for cancers were further discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, P.R. China.
- Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China.
- Department of Gynecological Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China.
- Xianghu Laboratory, Hangzhou, Zhejiang 311231, P.R. China.
Zitieren
APA
Xia, Y., Han, D., Tang, S., Yang, H., Zhao, R., Cao, B., Zhu, P., Shi, A., & Luo, H. (2026). Research progress of SPP1 in cancer regulation: Tumorigenesis, metastasis, tumor microenvironment, immunity and therapeutic targets (Review). International Journal of Oncology, 69(6), 1-22. https://doi.org/10.3892/ijo.2026.5949
Vancouver
Xia Y, Han D, Tang S, Yang H, Zhao R, Cao B, et al. Research progress of SPP1 in cancer regulation: Tumorigenesis, metastasis, tumor microenvironment, immunity and therapeutic targets (Review). International Journal of Oncology. 2026;69(6):1-22. doi:10.3892/ijo.2026.5949
BibTeX
@article{Xia2026,
author = {Xia, Yujun and Han, Dong and Tang, Song and Yang, Huimin and Zhao, Rongjie and Cao, Beibei and Zhu, Peixi and Shi, Aiqin and Luo, Huacheng},
title = {Research progress of SPP1 in cancer regulation: Tumorigenesis, metastasis, tumor microenvironment, immunity and therapeutic targets (Review)},
journal = {International Journal of Oncology},
year = {2026},
volume = {69},
number = {6},
pages = {1--22},
doi = {10.3892/ijo.2026.5949}
}
EUVIMED